Biopharma dealmaking skyrocketed in June 2025, reaching $35.07 billion, marking the highest monthly total of the year and contributing to a first-half 2025 deal value of $138.31 billion. This robust activity outpaces 2024 figures and surpasses full-year totals for numerous pre-2020 years, reflecting strengthened investor confidence and sustained mergers and acquisitions momentum in the biopharma sector.